News|Articles|November 30, 2015
Novotech Selected for Phase I Oncology Study
The Cantrixil Phase I study will be weighted towards ovarian cancer patients with the selection of a gynecological oncology site.
Advertisement
US-Australian drug discovery company, Novogen Limited announced it has engaged Novotech, based in Australia, as its CRO to conduct its Phase I clinical study for the drug candidate, Cantrixil, which will commence in 2016. The Cantrixil Phase I study will be weighted towards ovarian cancer patients with the selection of a gynecological oncology site. However, patients with other cancer types will also be eligible to enroll in this first study since early preclinical data suggests the drug candidate may benefit patients with a range of cancer types.
Read the full release .
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Articles
- Using AI Trial-Matching Tools to Accelerate Patient Access
September 8th 2025
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Pfizer, BioNTech’s Comirnaty Shows Strong Immune Response in Phase III Trial for COVID-19
2
Summit Therapeutics’ Bispecific Antibody Shows Positive Survival Trend in Non-Small Cell Lung Cancer
3
ACT Brief Episode 7: Veeva and Merck Trial Efficiency, DCT Barriers, and Glucose Monitoring Strategies
4
Beyond the Algorithm: How Human-Centered AI Design Can Drive Clinical Trial Success
5